Oxcarbazepine Tablet, Film Coated
Product Images NDC 51991-055

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 51991-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure diagram of oxcarbazepine, showing its bicyclic ring system with a ketone and amide functional groups as part of the molecule.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier curve comparing exit rates over time from day 2 to day 11 in a clinical trial. The graph shows two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). Exit rate is plotted on the y-axis from 0 to 1, and time on trial in days is on the x-axis. A log-rank test with a p-value of 0.0001 is displayed, indicating statistical comparison between groups.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve graph showing seizure rate over time in days from the first dose to the first seizure. It compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The graph includes a log-rank test p-value of 0.046 indicating statistical analysis of the difference between groups.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A line graph depicting exit rate over time in days for two treatment groups labeled HIGH (solid line) and LOW (dotted line). The y-axis shows exit rate from 0.0 to 1.0, and the x-axis shows time to exit from 0 to 130 days. A statistical note indicates a log-rank test p-value of 0.0001.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier curve chart showing exit rates over time (days) for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit in days from 0 to 130, and the y-axis represents exit rate from 0.0 to 1.0. The LOW group has a higher and faster exit rate compared to the HIGH group. The chart includes a log-rank test p-value of 0.0001 indicating statistical comparison of the two groups.*

FDA Label Image

Principal Display Panel (150 mg Tablet Bottle Label)

Label of Oxcarbazepine Tablets, USP 150 mg, film coated oral tablets. The package contains 100 tablets and is labeled by Breckenridge Pharmaceutical, Inc. The label includes storage instructions, a barcode, and distribution and manufacturing details from Breckenridge Pharmaceutical and Towa Pharmaceutical Europe, respectively.*

FDA Label Image

Principal Display Panel (300 mg Tablet Bottle Label)

The label is for Oxcarbazepine Tablets, USP, 300 mg film-coated oral tablets. The package contains 100 tablets. The labeler is Breckenridge Pharmaceutical, Inc., with manufacturing by Towa Pharmaceutical Europe, S.L. Storage conditions, dosage instructions reference, and a medication guide to dispense are noted. The NDC is 51991-054-01.*

FDA Label Image

Principal Display Panel (600 mg Tablet Bottle Label)

Label for Oxcarbazepine 600 mg film-coated tablets, USP, distributed by Breckenridge Pharmaceutical, Inc. The label states the product contains 100 tablets and includes storage instructions, dosage reference, manufacturer details (Towa Pharmaceutical Europe, S.L.), and an advisory to dispense the accompanying medication guide to each patient. The label also displays a barcode and NDC 51991-055-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.